LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) concerning the Company and its officers’ possible violations of federal securities laws.
The investigation concerns whether or not Zosano’s SEC filings in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”) contained any misleading or untrue statements. And, whether the Company adequately disclosed the risks and viability of its lead osteoporosis drug program, ZP-PTH, and Zosano’s partnership with Eli Lily and Co. Upon news of the alleged failure of the ZP-PTH to reach commercial viability, shares of the Company declined dramatically in value from the IPO share price of $11 per share; closing at $2.35 per share on April 7, 2016.
If you purchased Zosano securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.